StemCell Therapy

IRVINE, Calif., Oct. 4, 2022 /PRNewswire/ -- GATC Health ("GATC" or "the Company"), a science and technology company revolutionizing drug discovery and disease prediction using artificial intelligence (AI), today announced that the company is welcoming private investors to attend a GATC conference at Avenue of the Arts Hotel in Costa Mesa, CA on Wednesday, Oct. 5, for the first public demonstration of its proprietary Multiomics Advanced Technology (MAT) platform that discovers both small and large molecule drug candidates with 88% accuracy.

In addition to this demonstration, the agenda of the closed event includes key speakers from GATC Health as well as industry experts and thought leaders, who will provide additional context on how GATC's drug discovery and development abilities could be used in multiple areas of medicine, including addiction treatments, diabetes, oncology and other disease states.

GATC Health has attracted significant interest from sophisticated investors. The company expects its private conference to close its current Regulation D offering, representing the final opportunity for individuals to invest in the company. Invitations to GATC's event were limited to individuals who invested $100,000 or more in the company or who recently invested via referral. Following this round of funding, GATC Health is seeking institutional investment and is in conversations with several prospective funding institutions.

At the investor conference, GATC will also detail recent company developments, including a new study that shows its platform can predict drug candidate success with 88% accuracy, an increase to pre-clinical lead optimization 11x industry performance.

The company also recently announced a partnership with globally recognized music artist, entrepreneur and activist, Akon, to study and interpret genetic and other biological data to identify predisposition to diseases and enable life-saving preventative care for Africans and people of African heritage. Using the company's proprietary AI platform, which can process and analyze the entire human genome, the initiative will study the genetics of 1 million people across Africa and use that data to identify personalized healthcare solutions for the African participants, in addition to providing deep population health insights that can change the course of healthcare on the African continent.

Speakers at the day-long conference will include:

GATC Health company leadership scheduled to speak include:

About GATC HealthGATC Health Corp is a science and technology company using whole genome analysis and multiomics-based artificial intelligence to revolutionize disease detection and drug discovery. The company's patented AI platform reduces risk, time and costs for life science companies by digitally reproducing the human body to find non-obvious answers to biology's most complex questions. GATC Health is accelerating healthcare's transition to predictive, individualized medicine.

DISCLAIMER:Any offer to sell securities will be made only pursuant to a definitive fully executed Subscription Agreement and will be made in reliance on an exemption from registration under the United States Securities Act of 1933. Securities are offered by Entoro Securities, LLC, member of FINRA and SIPC. Additional disclosure information can be found at http://www.entoro.com/disclosures

SOURCE GATC Health

Original post:
GATC Health Investor Conference to Feature First Public Demonstration of Its AI Platform's Drug Discovery Capabilities - PR Newswire

This entry was posted on October 7, 2022 at 1:42 am and is filed under Molecular Genetics. You can follow any responses to this entry through the RSS 2.0 feed. Both comments and pings are currently closed. |